NCT05746416 (RICH) is a clinical trial in Coronary Artery Disease, sponsored by Hanyang University Seoul Hospital.

Who is sponsoring NCT05746416?

NCT05746416 is sponsored by Hanyang University Seoul Hospital.

What condition does NCT05746416 study?

NCT05746416 studies Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome.

Is NCT05746416 still recruiting?

NCT05746416 is currently completed. Last updated 27 February 2023.

Last reviewed 2023-02-27 · How we verify

NCT05746416: RICH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)

Completed Last updated 27 February 2023

What this trial tests

trial in Coronary Artery Disease in 977 participants. Completed in 31 December 2021.

Timeline

2 January 2019

Primary endpoint
31 December 2020

31 December 2021

Quick facts

Lead sponsor	Hanyang University Seoul Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	977
Start date	2 January 2019
Primary completion	31 December 2020
Estimated completion	31 December 2021
Sites	1 location across South Korea

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →

Sponsor

Hanyang University Seoul Hospital

Who can join

19 and older, any sex, with Coronary Artery Disease or Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to standard-dose TDAPT (ticagrelor 180mg daily; s-TDAPT) in outcomes of percutaneous coronary intervention (PCI). The main question it aims to answer are: Given the low ischemic risk and high bleeding tendency in Asians, the low dose TDAPT may provide better net clinical benefits of ischemic and bleeding events than the standard dose TDAPT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Influence of early dose reduction of ticagrelor on clinical outcomes following percutaneous coronary intervention for complex lesions.
Lee Y, Shin JH, Seo SM, Choi IJ, et al · · 2023 · cited 1× · PMID 37726368 · DOI 10.1038/s41598-023-42655-4

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Hanyang University Seoul Hospital trials

Trials by the same sponsor.

NCT06144021 — Efficacy and Safety of Kefir Whey Postbiotics · NA · recruiting
NCT06429644 — Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations · completed
NCT05164198 — REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) · Phase 4 · unknown
NCT04871945 — Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis · completed
NCT04567134 — Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05746416 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hanyang University Seoul Hospital
Last refreshed: 27 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05746416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing